THUMPD3 and thyroid gland carcinoma: For instance, LINC00957 was proved to be a potential biomarker and therapeutic target for colorectal cancer patients (18); LINC02532 was demonstrated to act as an oncogene in gastric cancer (GC) and promoted the GC cell proliferation, migration, and invasion (19); DOCK9-DT was revealed to play a protective role in the prognosis of thyroid carcinoma (20); THUMPD3-AS1 regulated non-small cell lung cancer cell self-renewal via the expression of miR-543 and ONECUT2, and THUMPD3-AS1 can serve as a potential biomarker or therapeutic target in non-small cell lung cancer (21).